T Cells Expressing NKG2D Chimeric Antigen Receptors Efficiently

Total Page:16

File Type:pdf, Size:1020Kb

T Cells Expressing NKG2D Chimeric Antigen Receptors Efficiently Yang et al. Journal for ImmunoTherapy of Cancer (2019) 7:171 J Immunother Cancer: first published as 10.1186/s40425-019-0642-9 on 9 July 2019. Downloaded from https://doi.org/10.1186/s40425-019-0642-9 RESEARCHARTICLE Open Access T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells Dong Yang1,3†, Bin Sun1,3†, Hongjiu Dai2*†, Wenxuan Li4, Lan Shi5, Peixian Zhang5, Shirong Li1 and Xudong Zhao1,3,6* Abstract Background: Traditional therapies fail to cure most glioblastoma patients and the 5-year survival rate is less than 10%, highlighting need for new therapeutic approaches. The natural killer group 2 member D ligands (NKG2DLs) are highly expressed in glioblastomas and are considered promising targets for chimeric antigen receptor (CAR) T-cell therapy. The aim of this study was to investigate the effect of NKG2D-expressing CAR-T cells on glioblastomas and glioblastoma stem cells. Methods: The expression of NKG2DLs was analyzed by flow cytometry and immunohistochemistry. NKG2D-BBz CAR, containing the extracellular domain of NKG2D, was constructed and delivered into T cells by lentiviral particles. In vitro cytotoxicity of the CAR-T cells was assessed by flow cytometry. Release of cytokine, perforin and granzyme B was quantified using enzyme-linked immunosorbent assay kits. The therapeutic efficacy of NKG2D-BBz CAR-T cells in vivo was evaluated using subcutaneous tumor models. The safety of the CAR was analyzed by investigating the effects on proliferation, apoptosis, and karyotype. Results: Our data confirmed the high expression of NKG2DLs in human glioblastoma cells, cancer stem cells, and tumor samples. Further, the NKG2D-BBz CAR-T cells efficiently lysed glioblastoma cells and cancer stem cells in vitro and produced high levels of cytokines, perforin, and granzyme B. The CAR-T cells markedly eliminated xenograft http://jitc.bmj.com/ tumors in vivo and did not exhibit significant treatment-related toxicity in the treated mice. The CAR expression also did not exert any obvious effects on cell proliferation, apoptosis, and genomic stability. Conclusion: Our findings demonstrated that NKG2D CAR-T cells targeted glioblastoma cells and cancer stem cells in an NKG2D-dependent manner, supporting the use of CAR-T therapy in glioblastoma therapeutic strategies. Keywords: Chimeric antigen receptor, Glioblastoma, Cancer stem cell, NKG2D on September 27, 2021 by guest. Protected copyright. Background 5-year survival rate of glioblastoma patients is still less than Glioblastoma is the most aggressive cancer of the central 10%, due to the biological complexity of brain tumors [1]. nervous system. Over the past few decades, although some The blood-brain barrier, a highly selective semipermeable progress has been made in traditional treatment options, border that separates the circulating blood from the brain consisting of surgery, radiotherapy, and chemotherapy, the and extracellular fluid in the central nervous system, pre- vents most cancer therapeutics from entering the brain par- enchyma [2]. Only three new treatments, with minor * Correspondence: [email protected]; [email protected] † improvement in prognosis, have been approved by the Dong Yang, Bin Sun and Hongjiu Dai are co-first authors. 2Nanjing Kaedi Biotech Co. Ltd, 18 Zhilan Road, Nanjing 211100, Jiangsu, FDA for glioblastoma since 2005, including temozolomide, China bevacizumab, and tumor-treating fields [3]. Therefore, there 1 Key Laboratory of Animal Models and Human Disease Mechanisms of is an urgent need to develop new treatment strategies for Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province, Kunming Institute of Zoology, Chinese Academy of glioblastoma. Sciences, 32 East Jiaochang Road, Kunming 650223, Yunnan, China Full list of author information is available at the end of the article © The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. Yang et al. Journal for ImmunoTherapy of Cancer (2019) 7:171 Page 2 of 13 J Immunother Cancer: first published as 10.1186/s40425-019-0642-9 on 9 July 2019. Downloaded from Recently, immunotherapy using engineered T cells NKG2DL dependent manner [20]. NKG2D ligand expressing chimeric antigen receptors (CAR) showed re- (NKG2DL) overexpression was reported in glioblastoma markable curative effects in multiple tumor types, espe- stem cells (GSCs), suggesting that NKG2D-expressing cially, in the case of hematologic malignancies [4]. CARs CAR-T cells may also have an effect on GSCs [21]. are artificial fusion proteins that include an extracellular In this study, we constructed CAR-T cells expressing antigen-binding domain, a transmembrane domain, and the extracellular domain of human NKG2D, as well as intracellular T-cell signaling domains (such as CD3ζ the 4-1BB and CD3ζ signaling domains, and investigated alone or in combination with one or more costimulatory the efficacy of these NKG2D-expressing CAR-T cells components) [5]. It’s reported that T cells can cross the against human glioblastoma cells and CSCs. blood-brain barrier and infiltrate the brain by diffusion [6]. Thus, CAR-T cell-based immunotherapy for glio- Methods blastomas could overcome the difficulty of drug delivery. Cell culture So far, CAR-T cells against IL-13Ra2, EGFRVIII, and U-251 MG, T98G, U-87 MG and HTB185 cell lines were HER2 have been tested in glioblastoma clinical treat- purchased from China Infrastructure of Cell Line Re- ment and have showed promising results [7–9]. More- sources (Kunming, China). The cells were tested via short over, CAR-T cell immunotherapy targeting EphA2, tandem repeat (STR) profiling in October 2018. The cells MUC1, EGFR, PD-L1, and PDPN are currently undergo- were cultured in DMEM containing 10% fetal bovine ing clinical studies in glioblastoma, but the results have serum (Millipore, USA), 100 U/ml penicillin, and 100 mg/ not yet been made public [10–12]. These reports indi- ml streptomycin (Life Technologies, USA). The GSC-3# cate that CAR-T cell therapy could be a new treatment cell line, isolated from primary glioblastoma tissues, was for glioblastoma patients. However, there are still some described previously [22]. U-251 MG and U-87 MG sus- limitations that prevent the application of such therap- pended cell spheres, named U251-CSC and U87-CSC, re- ies, such as the heterogeneity of glioblastoma and im- spectively, were established using serum-free neural stem munosuppression of tumor microenvironment. Thus, it cell medium composed of DMEM/F12, EGF (20 ng/ml, is still necessary to develop new CARs for the treatment Life Technologies, USA), bFGF (20 ng/ml, Life Technolo- of glioblastoma. Natural killer group 2 member D gies, USA), and B27 (1x, Life Technologies, USA) [23, 24]. (NKG2D) ligands, including two MHC class I-related All cell lines were cultured in a humidified incubator with chains and six UL16-binding proteins, were reported to 5% CO2 at 37 °C. be expressed at low levels in healthy human tissues and to be upregulated in most cancers [13]. NKG2D- Vector design expressing CARs were demonstrated to be effective The CD19 targeting domain and the extracellular do- http://jitc.bmj.com/ against most cancer types, such as multiple myeloma, main of human NKG2D was synthesized (Idobio, China) ovarian carcinoma, and lymphoma [14]. CAR-T cells ex- and cloned into a CAR-encoding lentivirus backbone pressing the full length murine NKG2D were also re- and named CD19-BBZ CAR and NKG2D-BBZ CAR, re- ported to remarkably prolong the survival of mice spectively, containing a CD8 hinge spacer and trans- bearing intracranial xenograft of mouse glioma cells membrane domain, 4-1BB, and CD3ζ endo-domains. [15]. However, the exact role of NKG2D-expressing The CARs were cloned into the LentiGuide-Puro plas- on September 27, 2021 by guest. Protected copyright. CARs in human glioblastoma remains to be elucidated. mid (Addgene, USA) and expressed under the control of The existence of cancer stem cells (CSCs) in glioblast- an EF1a promoter. oma is considered one of the major causes of the conven- tional therapy failure and cancer recurrence [16, 17]. Lentiviral package Previous studies have shown that the targeted killing of The lentiviral plasmids were co-transfected into CSCs could effectively inhibit glioblastoma tumorigenesis HEK293T cells with the packaging plasmids psPAX2 and and prolong the survival of glioma-bearing mice [18]. pCMV-VSVG (Addgene, USA) at a ratio of 10:8:5 as Therefore, development of specific and effective thera- described before [25]. peutic approaches to eliminate CSCs is urgently required. Due to the strong resistance to radiotherapy and chemo- CAR-T cell preparation therapy, immunotherapy shows more promising potential Blood collected from three healthy donors was used to to eradicate CSCs. Many surface markers of CSCs have isolated T cells respectively using the RosetteSep™ Hu- been used as target antigens for immunotherapy in cancer man T Cell Enrichment Cocktail (STEMCELL, Canada) treatment, such as CD133, CD90, ALDH, and EpCAM, and the T cells were cultured in RPMI 1640 medium and revealed encouraging anticancer activity [19]. Previ- (Life Technologies, USA) containing 10% FBS (Life ous studies have proved that natural killer cells could Technologies, USA) with 200 U/ml IL-2 (PeproTech, efficiently target osteosarcoma stem cells in an NKG2D- USA). T cells were activated by CD3/CD28 Dynabeads Yang et al. Journal for ImmunoTherapy of Cancer (2019) 7:171 Page 3 of 13 J Immunother Cancer: first published as 10.1186/s40425-019-0642-9 on 9 July 2019.
Recommended publications
  • NKG2D Signaling Within the Pancreatic Islets Reduces NOD Diabetes and Increases Protective Central Memory CD81 T-Cell Numbers
    Diabetes Volume 69, August 2020 1749 NKG2D Signaling Within the Pancreatic Islets Reduces NOD Diabetes and Increases Protective Central Memory CD81 T-Cell Numbers Andrew P. Trembath,1 Kelsey L. Krausz,1 Neekun Sharma,1 Ivan C. Gerling,2 Clayton E. Mathews,3 and Mary A. Markiewicz1 Diabetes 2020;69:1749–1762 | https://doi.org/10.2337/db19-0979 NKG2D is implicated in autoimmune diabetes. How- The immune receptor NKG2D, expressed by natural killer ever, the role of this receptor in diabetes pathogenesis (NK) cells and subsets of T cells (1–5), is implicated in type IMMUNOLOGY AND TRANSPLANTATION is unclear owing to conflicting results with studies in- 1 diabetes development. However, its role in disease pro- volving global inhibition of NKG2D signaling. We found gression remains unclear, with conflicting reports describ- that NKG2D and its ligands are present in human pan- ing pathogenic (6,7), nonpathogenic (8), and protective (9) creata, with expression of NKG2D and its ligands in- effects of NKG2D signaling. creased in the islets of patients with type 1 diabetes. NKG2D recognizes multiple NKG2D ligands in both To directly assess the role of NKG2D in the pancreas, we humans and mice. These are endogenous ligands, which generated NOD mice that express an NKG2D ligand in are all distantly related to MHC class I in sequence, and are b-islet cells. Diabetes was reduced in these mice. The generally believed to be functionally redundant (10,11). reduction corresponded with a decrease in the effector 1 NKG2D ligands are considered stress ligands, with their to central memory CD8 T-cell ratio.
    [Show full text]
  • Delineation of Natural Killer Cell Differentiation from Myeloid Progenitors in Human
    Delineation of Natural Killer Cell Differentiation from Myeloid Progenitors in Human The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters. Citation Chen, Qingfeng, Weijian Ye, Wei Jian Tan, Kylie Su Mei Yong, Min Liu, Shu Qi Tan, Eva Loh, et al. “Delineation of Natural Killer Cell Differentiation from Myeloid Progenitors in Human.” Scientific Reports 5 (October 12, 2015): 15118. As Published http://dx.doi.org/10.1038/srep15118 Publisher Nature Publishing Group Version Final published version Citable link http://hdl.handle.net/1721.1/100500 Terms of Use Creative Commons Attribution Detailed Terms http://creativecommons.org/licenses/by/4.0/ www.nature.com/scientificreports OPEN Delineation of Natural Killer Cell Differentiation from Myeloid Progenitors in Human Received: 01 July 2015 1,* 2,3,* 2 1 1 4 Accepted: 16 September 2015 Qingfeng Chen , Weijian Ye , Wei Jian Tan , Kylie Su Mei Yong , Min Liu , Shu Qi Tan , 5 5,6 4,6 2,3 2,7 Published: 12 October 2015 Eva Loh , Kenneth TE Chang , Thiam Chye Tan , Peter R Preiser & Jianzhu Chen Understanding of natural killer (NK) cell development in human is incomplete partly because of limited access to appropriate human tissues. We have developed a cytokine-enhanced humanized mouse model with greatly improved reconstitution and function of human NK cells. Here we report the presence of a cell population in the bone marrow of the cytokine-treated humanized mice that express both NK cell marker CD56 and myeloid markers such as CD36 and CD33. The CD56+CD33+CD36+ cells are also found in human cord blood, fetal and adult bone marrow.
    [Show full text]
  • Natural Killer Cell Lymphoma Shares Strikingly Similar Molecular Features
    Leukemia (2011) 25, 348–358 & 2011 Macmillan Publishers Limited All rights reserved 0887-6924/11 www.nature.com/leu ORIGINAL ARTICLE Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic cd T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro J Iqbal1, DD Weisenburger1, A Chowdhury2, MY Tsai2, G Srivastava3, TC Greiner1, C Kucuk1, K Deffenbacher1, J Vose4, L Smith5, WY Au3, S Nakamura6, M Seto6, J Delabie7, F Berger8, F Loong3, Y-H Ko9, I Sng10, X Liu11, TP Loughran11, J Armitage4 and WC Chan1, for the International Peripheral T-cell Lymphoma Project 1Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA; 2Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE, USA; 3Departments of Pathology and Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong, China; 4Division of Hematology and Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA; 5College of Public Health, University of Nebraska Medical Center, Omaha, NE, USA; 6Departments of Pathology and Cancer Genetics, Aichi Cancer Center Research Institute, Nagoya University, Nagoya, Japan; 7Department of Pathology, University of Oslo, Norwegian Radium Hospital, Oslo, Norway; 8Department of Pathology, Centre Hospitalier Lyon-Sud, Lyon, France; 9Department of Pathology, Samsung Medical Center, Sungkyunkwan University, Seoul, Korea; 10Department of Pathology, Singapore General Hospital, Singapore and 11Penn State Hershey Cancer Institute, Pennsylvania State University College of Medicine, Hershey, PA, USA Natural killer (NK) cell lymphomas/leukemias are rare neo- Introduction plasms with an aggressive clinical behavior.
    [Show full text]
  • Regulation and Genetic Manipulation of Ligands for the Immunoreceptor NKG2D
    Regulation and Genetic Manipulation of Ligands for the Immunoreceptor NKG2D by Benjamin Gregory Gowen A dissertation submitted in partial satisfaction of the requirements for the degree of Doctor of Philosophy in Molecular and Cell Biology in the Graduate Division of the University of California, Berkeley Committee in charge: Professor David H. Raulet, Chair Professor Gregory M. Barton Professor Michael Rape Professor Karsten Gronert Spring 2015 Abstract Regulation and Genetic Manipulation of Ligands for the Immunoreceptor NKG2D by Benjamin Gregory Gowen Doctor of Philosophy in Molecular and Cell Biology University of California, Berkeley Professor David H. Raulet, Chair NKG2D is an important activating receptor expressed by natural killer (NK) cells and some subsets of T cells. NKG2D recognizes a family of cell surface protein ligands that are typically not expressed by healthy cells, but become upregulated by cellular stress associated with transformation or infection. Engagement of NKG2D by its ligands displayed on a target cell membrane leads to NK cell activation, cytokine secretion, and lysis of the target cell. Despite the importance of NKG2D for controlling tumors, the molecular mechanisms driving NKG2D ligand expression on tumor cells are not well defined. The work described in this dissertation was centered on the identification of novel regulators of ULBP1, one of the human NKG2D ligands. Using a forward genetic screen of a tumor-derived human cell line, we identified several novel factors supporting ULBP1 expression, and used the CRISPR/Cas9 system to further investigate these hits. Our results showed stepwise contributions of independent pathways working at multiple stages of ULBP1 biogenesis, including transcription of the ULBP1 gene, splicing of the ULBP1 mRNA, and additional co-translational or post-translational regulation of the ULBP1 protein.
    [Show full text]
  • NKG2D and Related Immunoreceptors
    NKG2D and related immunoreceptors Roland K. Strong1* and Benjamin J. McFarland2 1Division of Basic Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. North, Seattle, WA 98109 2Department of Chemistry and Biochemistry, Seattle Pacific University, 3307 Third Avenue West, Seattle WA 98119 *email address: [email protected] Abstract NK cells are crucial components of the innate immune system, capable of directly eliminating infected or tumorigenic cells and regulating down-stream adaptive immune responses. Unlike T cells, where the key recognition event driving activation is mediated by the unique T cell receptor (TCR) expressed on a given cell, NK cells express multiple activating and inhibitory cell-surface receptors (NKRs), often with overlapping ligand specificities. NKRs display two ectodomain structural homologies, either immunoglobulin- or C-type lectin-like (CTLD). The CTLD immunoreceptor NKG2D is found on NK cells but is also widely expressed on T cells and other immune system cells, providing stimulatory or co- stimulatory signals. NKG2D drives target cell killing following engagement of diverse, conditionally expressed MHC class I-like protein ligands whose expression can signal cellular distress due to infection or transformation. The symmetric, homodimeric receptor interacts with its asymmetric, monomeric ligands in similar 2:1 complexes, with an equivalent surface on each NKG2D monomer binding extensively and intimately to distinct, structurally divergent surfaces on the ligands. Thus, NKG2D ligand-binding site recognition is highly degenerate, further demonstrated by NKG2D’s ability to simultaneously accommodate multiple non-conservative allelic or isoform substitutions in the ligands. In TCRs, ‘induced-fit’ recognition explains cross-reactivity, but structural, computational, thermodynamic and kinetic analyses of multiple NKG2D–ligand pairs show that rather than classical ‘induced-fit’ binding, NKG2D degeneracy is achieved using distinct interaction mechanisms at each rigid interface: recognition degeneracy by ‘rigid adaptation’.
    [Show full text]
  • Comparative Analysis of Human NK Cell Activation Induced by NKG2D and Natural Cytotoxicity Receptors
    Eur. J. Immunol. 2004. 34: 961–971 NK cell activation by NKG2D and NCR 961 Comparative analysis of human NK cell activation induced by NKG2D and natural cytotoxicity receptors Pascale Andre ´ 1,RobertaCastriconi2,MarionEsp´eli3, Nicolas Anfossi3,Tiffany Juarez4,SophieHue5, Holli Conway1,Fran¸cois Romagne ´ 1, Alessandra Dondero2, Marina Nanni6, Sophie Caillat-Zucman5, David H. Raulet4,CristinaBottino6,Eric Vivier3, Alessandro Moretta2,7 and Pascale Paul3 1 Innate-Pharma SA, Marseille, France 2 Molecular Immunology laboratories, Dipartimento di Medicina Sperimentale, Sezione di Istologia, University of Genova, Genova, Italy 3 Centre d’Immunologie de Marseille-Luminy, CNRS-INSERM-UniversitedelaM´ ´ editerranee, ´ Marseille, France 4 Department of Molecular and Cell Biology and Cancer Research Laboratory, University of California, Berkeley, USA 5 Laboratoire d’Immunologie and Equipe Avenir INSERM, IFR94, Hopital ˆ Necker, Paris, France 6 Istituto Giannina Gaslini, Genova, Genova, Italy 7 Centro di Eccellenza per le Ricerche Biomediche, University of Genova, Genova, Italy NKG2D and natural cytotoxicity receptors (NCR) are essential recognition structures that mediate NK cell activation. NKG2D and NCR signaling is achieved through membrane asso- ciation with signaling adaptors. The adaptors that associate with NCR — such as CD3 ´ , FcR + and KARAP/DAP12 — bear intracytoplasmic immunoreceptor tyrosine-based activa- tion motifs that activate Syk protein tyrosine kinases. Human NKG2D associates with the DAP10 transmembrane adaptor, which bears a YxxM motif and activates the phosphatidyl- inositol 3-kinase pathway. In the mouse, a short NKG2D-S isoform, generated by Nkg2d alternative splicing, can associate with either DAP10 or KARAP/DAP12. Here, we report that neither short human NKG2D alternative transcripts nor NKG2D association with KARAP/ DAP12 was detected in activated human NK cells.
    [Show full text]
  • Role of NKG2D in Obesity-Induced Adipose Tissue Inflammation and Insulin Resistance Jun-Jae Chung Washington University School of Medicine in St
    Washington University School of Medicine Digital Commons@Becker Open Access Publications 2014 Role of NKG2D in obesity-induced adipose tissue inflammation and insulin resistance Jun-Jae Chung Washington University School of Medicine in St. Louis Mary A. Markiewicz Washington University School of Medicine in St. Louis Bojan Polic University of Rijeka School of Medicine Andrey S. Shaw Washington University School of Medicine in St. Louis Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs Recommended Citation Chung, Jun-Jae; Markiewicz, Mary A.; Polic, Bojan; and Shaw, Andrey S., ,"Role of NKG2D in obesity-induced adipose tissue inflammation and insulin resistance." PLoS One.9,10. e110108. (2014). https://digitalcommons.wustl.edu/open_access_pubs/3408 This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact [email protected]. Role of NKG2D in Obesity-Induced Adipose Tissue Inflammation and Insulin Resistance Jun-Jae Chung1, Mary A. Markiewicz1¤, Bojan Polic´2, Andrey S. Shaw1,3* 1 Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, United States of America, 2 Department of Histology and Embryology, University of Rijeka School of Medicine, Rijeka, Croatia, 3 Howard Hughes Medical Institute, Washington University School of Medicine, St. Louis, Missouri, United States of America Abstract The early events that initiate inflammation in the adipose tissue during obesity are not well defined. It is unclear whether the recruitment of CD8 T cells to the adipose tissue during onset of obesity occurs through antigen-dependent or - independent processes.
    [Show full text]
  • NKG2D Ligands in Tumor Immunity
    Oncogene (2008) 27, 5944–5958 & 2008 Macmillan Publishers Limited All rights reserved 0950-9232/08 $32.00 www.nature.com/onc REVIEW NKG2D ligands in tumor immunity N Nausch and A Cerwenka Division of Innate Immunity, German Cancer Research Center, Im Neuenheimer Feld 280, Heidelberg, Germany The activating receptor NKG2D (natural-killer group 2, activated NK cells sharing markers with dendritic cells member D) and its ligands play an important role in the (DCs), which are referred to as natural killer DCs NK, cd þ and CD8 þ T-cell-mediated immune response to or interferon (IFN)-producing killer DCs (Pillarisetty tumors. Ligands for NKG2D are rarely detectable on the et al., 2004; Chan et al., 2006; Taieb et al., 2006; surface of healthy cells and tissues, but are frequently Vosshenrich et al., 2007). In addition, NKG2D is expressed by tumor cell lines and in tumor tissues. It is present on the cell surface of all human CD8 þ T cells. evident that the expression levels of these ligands on target In contrast, in mice, expression of NKG2D is restricted cells have to be tightly regulated to allow immune cell to activated CD8 þ T cells (Ehrlich et al., 2005). In activation against tumors, but at the same time avoid tumor mouse models, NKG2D þ CD8 þ T cells prefer- destruction of healthy tissues. Importantly, it was recently entially accumulate in the tumor tissue (Gilfillan et al., discovered that another safeguard mechanism controlling 2002; Choi et al., 2007), suggesting that the activation via the receptor NKG2D exists. It was shown NKG2D þ CD8 þ T-cell population comprises T cells that NKG2D signaling is coupled to the IL-15 receptor involved in tumor cell recognition.
    [Show full text]
  • NKG2D Controls Natural Reactivity of Vg9vd2 T Lymphocytes Against
    Published OnlineFirst September 10, 2019; DOI: 10.1158/1078-0432.CCR-19-0375 Translational Cancer Mechanisms and Therapy Clinical Cancer Research NKG2D Controls Natural Reactivity of Vg9Vd2T Lymphocytes against Mesenchymal Glioblastoma Cells Cynthia Chauvin1,2,Noemie Joalland1,2, Jeanne Perroteau1,2, Ulrich Jarry1,2, Laura Lafrance1,2, Catherine Willem1,3, Christelle Retiere 1,3, Lisa Oliver1,4, Catherine Gratas1,4, Laetitia Gautreau-Rolland1,2, Xavier Saulquin1,2, Francois¸ M. Vallette1,2,5, Henri Vie1,2, Emmanuel Scotet1,2, and Claire Pecqueur1,2 Abstract Purpose: Cellular immunotherapies are currently being Results: We evidenced that GBM cells displaying a mes- explored to eliminate highly invasive and chemoradioresistant enchymal signature are spontaneously eliminated by allo- glioblastoma (GBM) cells involved in rapid relapse. We recent- geneic human Vg9Vd2 T lymphocytes, a reactivity process ly showed that concomitant stereotactic injections of non- being mediated by gd T-cell receptor (TCR) and tightly alloreactive allogeneic Vg9Vd2 T lymphocytes eradicate regulated by cellular stress–associated NKG2D pathway. zoledronate-primed human GBM cells. In the present study, This led to the identification of highly reactive Vg9Vd2T we investigated the spontaneous reactivity of allogeneic lymphocyte populations, independently of a specificTCR human Vg9Vd2 T lymphocytes toward primary human GBM repertoire signature. Moreover, we finally provide evidence cells, in vitro and in vivo, in the absence of any prior of immunotherapeutic efficacy in vivo, in the absence of any sensitization. prior tumor cell sensitization. Experimental Design: Through functional and transcrip- Conclusions: By identifying pathways implicated in the tomic analyses, we extensively characterized the immuno- selective natural recognition of mesenchymal GBM cell reactivity of human Vg9Vd2 T lymphocytes against various subtypes, accounting for 30% of primary diagnosed and primary GBM cultures directly derived from patient 60% of recurrent GBM, our results pave the way for novel tumors.
    [Show full text]
  • Antigen-Induced but Not Innate Memory CD8 T Cells Express NKG2D and Are Recruited to the Lung Parenchyma Upon Viral Infection
    bioRxiv preprint doi: https://doi.org/10.1101/224782; this version posted November 25, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Antigen-induced but not innate memory CD8 T cells express NKG2D and are recruited to the lung parenchyma upon viral infection Morgan Grau1, Séverine Valsesia1, Julien Mafille1, Sophia Djebali1, Martine Tomkowiak1, Anne-Laure Mathieu1, Daphné Laubreton1, Simon de Bernard2, Pierre- Emmanuel Jouve2, Laurent Buffat2, Thierry Walzer1, Yann Leverrier1, Jacqueline Marvel1. 1 CIRI, Centre International de Recherche en Infectiologie, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Univ Lyon, F-69007, LYON, France 2 Altrabio, Lyon, France Corresponding author: Jacqueline Marvel Team Immunity and cytotoxic lymphocytes, CIRI, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Univ Lyon. 21 Avenue Tony Garnier - 69365 LYON cedex 07, France. Tel +33437287655. E- mail: [email protected] Character count: 39500 Short title: Innate versus antigen-induced memory CD8 T cells 1 bioRxiv preprint doi: https://doi.org/10.1101/224782; this version posted November 25, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract The pool of memory-phenotype CD8 T cells is composed of antigen-induced (AI) and cytokine-induced innate (IN) cells. IN have been described as having similar properties to AI memory cells. However, we found that pathogen-induced AI memory cells can be distinguished from naturally-generated IN memory cells by surface expression of NKG2D.
    [Show full text]
  • Datasheet: MCA1441 Product Details
    Datasheet: MCA1441 Description: MOUSE ANTI RAT CD11c Specificity: CD11c Other names: INTEGRIN ALPHA X CHAIN Format: Purified Product Type: Monoclonal Antibody Clone: 8A2 Isotype: IgG2a Quantity: 0.25 mg Product Details Applications This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols. Yes No Not Determined Suggested Dilution Flow Cytometry 1/10 - 1/50 Immunohistology - Frozen 10ug/ml Immunohistology - Paraffin ELISA Immunoprecipitation Western Blotting Immunofluorescence Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls. Target Species Rat Product Form Purified IgG - liquid Preparation Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant Buffer Solution Phosphate buffered saline Preservative 0.09% Sodium Azide Stabilisers Approx. Protein IgG concentration 1.0 mg/ml Concentrations Immunogen Rat alveolar macrophages. External Database UniProt: Page 1 of 3 Links Q9QYE7 Related reagents Entrez Gene: 64350 Itgad Related reagents Synonyms Itgax Fusion Partners Spleen cells from immunised BALB/c mice were fused with cells of the mouse SP2/0 myeloma cell line. Specificity Mouse anti Rat CD11c antibody, clone 8A2 recognizes the rat CD11c, also know as Integrin Alpha-X or Integrin Alpha-D, cell surface antigen, expressed by some myeloid cells and dendritic cells.
    [Show full text]
  • NKG2D−NKG2D Ligand Interaction Inhibits the Outgrowth of Naturally Arising Low-Grade B Cell Lymphoma in Vivo
    NKG2D−NKG2D Ligand Interaction Inhibits the Outgrowth of Naturally Arising Low-Grade B Cell Lymphoma In Vivo This information is current as Saravanan Raju, Lena Z. Kretzmer, Olivia I. Koues, of September 29, 2021. Jacqueline E. Payton, Eugene M. Oltz, Amanda Cashen, Bojan Polic, Robert D. Schreiber, Andrey S. Shaw and Mary A. Markiewicz J Immunol published online 2 May 2016 http://www.jimmunol.org/content/early/2016/04/30/jimmun Downloaded from ol.1501982 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 29, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published May 2, 2016, doi:10.4049/jimmunol.1501982 The Journal of Immunology NKG2D–NKG2D Ligand Interaction Inhibits the Outgrowth of Naturally Arising Low-Grade B Cell Lymphoma In Vivo Saravanan Raju,* Lena Z. Kretzmer,* Olivia I. Koues,* Jacqueline E. Payton,* Eugene M. Oltz,* Amanda Cashen,† Bojan Polic,‡ Robert D.
    [Show full text]